“Hidradenitis Suppurativa Pipeline Insight, 2025“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Hidradenitis Suppurativa Market.
The Hidradenitis Suppurativa Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Hidradenitis Suppurativa Pipeline Report:
Companies across the globe are diligently working toward developing novel Hidradenitis Suppurativa treatment therapies with a considerable amount of success over the years.
Hidradenitis Suppurativa companies working in the treatment market are Kymera Therapeutics, CSL Behring, Azora Therapeutics, Union Therapeutics, Eli Lilly and company, Boehringer Ingelheim, ACELYRIN, Incyte Corporation, InflaRx, Novartis, ChemoCentryx, Janssen Pharmaceutical/XBiotech, Aclaris Therapeutics, and others, are developing therapies for the Hidradenitis Suppurativa treatment
Emerging Hidradenitis Suppurativa therapies in the different phases of clinical trials are- KT-474, CSL324, AT193, Orismilast, LY3041658, Spesolimab, Izokibep, INCB054707, IFX-1, Cosentyx/Secukinumab, Avacopan, Bermekimab, Zunsemetinib (ATI-450), and others are expected to have a significant impact on the Hidradenitis Suppurativa market in the coming years.
In March 2025, Incyte (Nasdaq: INCY) has reported promising topline results from its pivotal Phase 3 STOP-HS clinical program, which evaluated the safety and efficacy of povorcitinib (INCB054707)—an oral small-molecule JAK1 inhibitor—in adults aged 18 and above with moderate to severe hidradenitis suppurativa (HS). Both the STOP-HS1 and STOP-HS2 studies met their primary endpoints for the two tested doses (45 mg and 75 mg).
In March 2025, UCB, a global biopharmaceutical company, has released two-year data from the BE HEARD^ trials assessing BIMZELX® (bimekizumab-bkzx) for treating moderate-to-severe hidradenitis suppurativa (HS). BIMZELX is the first and only approved therapy that specifically targets both interleukin 17A (IL-17A) and interleukin 17F (IL-17F). The findings highlight the drug’s continued effectiveness in delivering lasting symptom relief and consistent disease management, with promising potential to reduce the risk of long-term structural damage caused by draining tunnels (DTs).
Hidradenitis Suppurativa Overview
Hidradenitis Suppurativa is a chronic skin condition characterized by painful, inflamed lumps, abscesses, and scarring, usually occurring in areas with sweat glands like the armpits, groin, and under the breasts. It results from blocked hair follicles and causes recurrent flare-ups, leading to discomfort and potential infection. The exact cause is unclear, but it is linked to inflammation and sometimes genetic factors.
Get a Free Sample PDF Report to know more about Hidradenitis Suppurativa Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/hidradenitis-suppurativa-pipeline-insight
Emerging Hidradenitis Suppurativa Drugs Under Different Phases of Clinical Development Include:
KT-474: Kymera Therapeutics
CSL324: CSL Behring
AT193: Azora Therapeutics
Orismilast: Union Therapeutics
LY3041658: Eli Lilly and company
Spesolimab: Boehringer Ingelheim
Izokibep: ACELYRIN
INCB054707: Incyte Corporation
IFX-1: InflaRx
Cosentyx/Secukinumab: Novartis
Avacopan: ChemoCentryx
Bermekimab: Janssen Pharmaceutical/XBiotech
Zunsemetinib (ATI-450): Aclaris Therapeutics
Hidradenitis Suppurativa Route of Administration
Hidradenitis Suppurativa pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
Oral
Parenteral
Intravenous
Subcutaneous
Topical
Hidradenitis Suppurativa Molecule Type
Hidradenitis Suppurativa Products have been categorized under various Molecule types, such as
Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy
Hidradenitis Suppurativa Pipeline Therapeutics Assessment
Hidradenitis Suppurativa Assessment by Product Type
Hidradenitis Suppurativa By Stage and Product Type
Hidradenitis Suppurativa Assessment by Route of Administration
Hidradenitis Suppurativa By Stage and Route of Administration
Hidradenitis Suppurativa Assessment by Molecule Type
Hidradenitis Suppurativa by Stage and Molecule Type
DelveInsight’s Hidradenitis Suppurativa Report covers around 24+ products under different phases of clinical development like
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Further Hidradenitis Suppurativa product details are provided in the report. Download the Hidradenitis Suppurativa pipeline report to learn more about the emerging Hidradenitis Suppurativa therapies
Some of the key companies in the Hidradenitis Suppurativa Therapeutics Market include:
Key companies developing therapies for Hidradenitis Suppurativa are – InflaRx, Novartis, UCB, AbbVie, Pfizer, Amgen, Incyte Corporation, CSL Behring, ChemoCentryx, Eli Lilly and Company, Janssen Biotech, Kymera Therapeutics, Aclaris Therapeutics, Boehringer Ingelheim, Azora Therapeutics, and others.
Hidradenitis Suppurativa Pipeline Analysis:
The Hidradenitis Suppurativa pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Hidradenitis Suppurativa with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hidradenitis Suppurativa Treatment.
Hidradenitis Suppurativa key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Hidradenitis Suppurativa Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Hidradenitis Suppurativa market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Hidradenitis Suppurativa drugs and therapies
Hidradenitis Suppurativa Pipeline Market Drivers
Increase in the incidence of chronic inflammatory skin diseases, large number of ongoing clinical trials, increasing knowledge about skin diseases are some of the important factors that are fueling the Hidradenitis Suppurativa Market.
Hidradenitis Suppurativa Pipeline Market Barriers
However, high cost of therapy, side-effects associated and other factors are creating obstacles in the Hidradenitis Suppurativa Market growth.
Scope of Hidradenitis Suppurativa Pipeline Drug Insight
Coverage: Global
Key Hidradenitis Suppurativa Companies: Kymera Therapeutics, CSL Behring, Azora Therapeutics, Union Therapeutics, Eli Lilly and company, Boehringer Ingelheim, ACELYRIN, Incyte Corporation, InflaRx, Novartis, ChemoCentryx, Janssen Pharmaceutical/XBiotech, Aclaris Therapeutics, and others
Key Hidradenitis Suppurativa Therapies: KT-474, CSL324, AT193, Orismilast, LY3041658, Spesolimab, Izokibep, INCB054707, IFX-1, Cosentyx/Secukinumab, Avacopan, Bermekimab, Zunsemetinib (ATI-450), and others
Hidradenitis Suppurativa Therapeutic Assessment: Hidradenitis Suppurativa current marketed and Hidradenitis Suppurativa emerging therapies
Hidradenitis Suppurativa Market Dynamics: Hidradenitis Suppurativa market drivers and Hidradenitis Suppurativa market barriers
Request for Sample PDF Report for Hidradenitis Suppurativa Pipeline Assessment and clinical trials
Table of Contents
1. Hidradenitis Suppurativa Report Introduction
2. Hidradenitis Suppurativa Executive Summary
3. Hidradenitis Suppurativa Overview
4. Hidradenitis Suppurativa- Analytical Perspective In-depth Commercial Assessment
5. Hidradenitis Suppurativa Pipeline Therapeutics
6. Hidradenitis Suppurativa Late Stage Products (Phase II/III)
7. Hidradenitis Suppurativa Mid Stage Products (Phase II)
8. Hidradenitis Suppurativa Early Stage Products (Phase I)
9. Hidradenitis Suppurativa Preclinical Stage Products
10. Hidradenitis Suppurativa Therapeutics Assessment
11. Hidradenitis Suppurativa Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Hidradenitis Suppurativa Key Companies
14. Hidradenitis Suppurativa Key Products
15. Hidradenitis Suppurativa Unmet Needs
16 . Hidradenitis Suppurativa Market Drivers and Barriers
17. Hidradenitis Suppurativa Future Perspectives and Conclusion
18. Hidradenitis Suppurativa Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media ContactCompany Name: DelveInsightContact Person: Gaurav BoraEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/
